中国胸心血管外科临床杂志

中国胸心血管外科临床杂志

婴幼儿先心病肺动脉高压合并唐氏综合征的外科治疗

查看全文

目的 探讨婴幼儿先心病肺动脉高压合并唐氏综合征的治疗方法。 方法 回顾性分析 2015 年 3 月至 2016 年 8 月在本院收治的先天性心脏病合并肺动脉高压 60 例患儿的临床资料。其中 30 例患儿合并唐氏综合征为试验组,另外 30 例患儿为对照组。两组患儿均行择期手术治疗,并于术后给予法舒地尔联合西地那非治疗肺动脉高压。 结果 两组患儿术中体外循环时间、主动脉阻断时间、改良超滤时间和术后呼吸道并发症发生率无显著差异。与术前相比,两组患儿术后 24 h 肺动脉收缩压均有显著下降(P 均<0.05)。与对照组相比,试验组患儿术后 6 h 氧分压和氧合指数均显著降低(P 均<0.05)。试验组患儿术后机械通气时间和重症监护时间较对照组延长(分别为P=0.007 和 P=0.000)。无近期死亡和再手术患者。 结论 婴幼儿先天性心脏病肺动脉高压合并唐氏综合征围手术期具有较高的肺部并发症发生率。通过严格把握适应证和术后早期完善肺保护、控制肺动脉高压等措施,多数患儿能够通过手术获得理想的治疗效果。

Objective To explore the treatment method of congenital heart disease (CHD) with pulmonary artery hypertension (PAH) in infants with Down syndrome (DS). Methods Sixty CHD patients with PAH from March 2015 to August 2016 were retrospectively analysed. There were 30 infants were diagnosed as a DS group (trial group) and the other 30 patients were classified as a control group. All the patients underwent surgical treatment and fasudil combined with sildenafil were used to prevent pulmonary hypertension crisis postoperatively. Results There were no significant differences in cardiopulmonary bypass time, aortic cross-clamping time, modified ultrafiltration time and the incidence of postoperative respiratory complications between the two groups. The pulmonary systolic blood pressure significantly decreased at 24 h after operation (both P<0.05). The arterial oxygen pressure and oxygenation index of the trial group were lower than that of the control group at 6 h after operation (bothP<0.05). The mechanical ventilation time and intensive care time of the trial group were significantly longer than those of the control group (P=0.007 and P=0.000, respectively). There were no reoperations or early death. Conclusion The effects of surgical repair of congenital heart disease with PAH in infants with DS were satisfactory by grasping the indication, protecting lung function and controlling of PAH in the early postoperative period, although there is a high incidence of pulmonary complication.

关键词: 婴幼儿; 唐氏综合征; 先天性心脏病; 肺动脉高压

Key words: Infants; Down syndrome; congenital heart disease; pulmonary artery hypertension

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Saji T. Clinical characteristics of pulmonary arterial hypertension associated with Down syndrome. Pediatr Int, 2014, 56(3): 297-303.
2. Fudge JC Jr, Li S, Jaggers J, et al. Congenital heart surgery outcomes in Down syndrome: analysis of a national clinical database. Pediatrics, 2010, 126(2): 315-322.
3. 刘迎龙. 先天性心脏病相关肺动脉高压的临床诊治. 心肺血管病杂志, 2015, 34(11): 809-811.
4. 高伟, 顾红, 胡大一, 等. 2015 年先天性心脏病相关性肺动脉高压诊治中国专家共识. 中国介入心脏病学杂志, 2015, 23(2): 61-69.
5. 张小贞, 李刚, 王树伟, 等. 优化改良超滤用于婴幼儿心脏手术的临床效果研究. 中国体外循环杂志, 2018, 16(2): 76-79.
6. Haeck ML, Vliegen HW. Diagnosis and treatment of pulmonary hypertension. Heart, 2015, 101(4): 311-319.
7. 张国富, 刘宏宇. 肺动脉高压治疗的进展. 中国胸心血管外科临床杂志, 2015, 22(12): 1157-1162.
8. Cua CL, Rogers LK, Chicoine LG, et al. Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine. Eur J Pediatr, 2011, 170(7): 859-863.
9. Cannon BC, Feltes TF, Fraley JK, et al. Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response. Pediatr Cardiol, 2005, 26(5): 565-569.
10. D’Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down’s syndrome. Int J Cardiol, 2013, 164(3): 323-326.
11. 刘义敏, 王辉, 杨宇强, 等. 内皮素受体拮抗剂在围术期治疗 6 个月以下婴儿肺动脉高压的临床意义. 中国胸心血管外科临床杂志, 2011, 18(5): 478-480.
12. 范长生, 吴久鸿. 波生坦片治疗肺动脉高压成本-效用分析. 药品评价, 2016, 13(8): 13-19.
13. Ziino AJ, Ivanovska J, Belcastro R, et al. Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia. Pediatr Res, 2010, 67(2): 177-182.
14. Firth AL, Choi IW, Park WS. Animal models of pulmonary hypertension: Rho kinase inhibition. Prog Biophys Mol Biol, 2012, 109(3): 67-75.
15. Mouchaers KT, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J, 2010, 36(4): 800-807.
16. Antoniu SA. Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert Opin Ther Targets, 2012, 16(4): 355-363.
17. Galambos C. Alveolar Capillary Dysplasia in a Patient with Down’s Syndrome. Pediatr Dev Pathol, 2006, 9(3): 254-255.
18. Shehata BM, Abramowsky CR. Alveolar capillary dysplasia in an infant with trisomy 21. Pediatr Dev Pathol, 2005, 8(6): 696-700.